'Dishman Carbogen Amcis released a presentation on medical therapies and their market scope.
Oncology continues as the largest spending therapy area with growth projected in the 14% to 17% range through 2028 as new treatments continue to be launched. Oncology (cancer treatment) requires highly potent drugs which are highly effective at much smaller dosages and have the ability to target only the diseased cells. Specialty medicines will represent about 43% of global spending in 2028 and 55% of total spending in developed markets.
The company focuses on oncology and currently has 14 molecules in phase III. Out of these, many molecules are in Oncology segment. It is also a preferred global outsourcing partner. It comprises of a drug lifecycle management, strong R&D Capabilities, close proximity to clients with global presence and large scale manufacturing capacity.
Outlook
Dishman Carbogen Amcis is well-positioned for strong growth, leverag...
Pleaselogin & subscribe to view the full report.
More Reports
|